# MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

> **NCT00207103** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 68 (actual)

## Conditions studied

- Tumors
- Neoplasm Metastasis

## Interventions

- **DRUG:** Brivanib
- **DRUG:** Brivanib
- **DRUG:** Brivanib
- **DRUG:** Brivanib
- **DRUG:** Brivanib
- **DRUG:** Brivanab

## Key facts

- **NCT ID:** NCT00207103
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-10
- **Final completion:** 2008-09
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2008-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207103, "MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00207103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*